Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Drug Production

Eli Lilly is investing an additional $5.3 billion to expand its Lebanon, Indiana site, increasing the total investment to $9 billion to meet the high demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro.

Eli Lilly and Company is significantly increasing its investments to bolster manufacturing capabilities, particularly for its newly introduced drugs, Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection. The pharmaceutical giant has announced an additional $5.3 billion investment in its Lebanon, Indiana, facility, bringing the total investment in this location to a monumental $9 billion. This move aims to enhance the production of active pharmaceutical ingredients (APIs) for these treatments, addressing the growing demand among adults with chronic diseases such as obesity and type 2 diabetes.

Since 2020, Eli Lilly has dedicated over $16 billion towards establishing new manufacturing sites in the U.S. and Europe. This sprawling manufacturing expansion includes sites beyond Indiana, such as in Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany. Additionally, the company has invested $1.2 billion in upgrading existing facilities in Indianapolis and acquiring an injectable manufacturing facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals. Cumulatively, these investments exceed $18 billion, marking a significant stride in pharmaceutical manufacturing.

David A. Ricks, Eli Lilly's chair and CEO, highlighted the unprecedented nature of this investment, emphasizing its scale as the largest in U.S. history for the manufacturing of synthetic medicine APIs. This strategic investment is especially poignant for the Lebanon site, situated within Indiana's LEAP Research and Innovation District, propelling it to become a multi-site campus dedicated to producing Eli Lilly's latest medicines, supporting pipeline growth, and utilizing cutting-edge technology for operational efficiency, safety, and quality control.

The investment comes in the wake of compelling research results for tirzepatide, with Lilly making a calculated decision to ramp up manufacturing capacity in anticipation of the drug's approval. Mounjaro was approved in 2022, followed by Zepbound in 2023, both meeting critical demand as the only approved treatments activating two incretin hormone receptors, GIP, and GLP-1, addressing significant unmet needs in the treatment of type 2 diabetes and obesity.

The expanded Lebanon facility is expected to create 200 full-time jobs for highly skilled professionals, including engineers, scientists, and technicians, bringing the expected total workforce to approximately 900 once fully operational. This expansion is also set to generate over 5,000 construction jobs throughout the site's development phase.

Indiana Governor Eric J. Holcomb praised Lilly's continued investment in the state, acknowledging its transformational role in driving global innovation and economic growth. The state has pledged to partner with Lilly on infrastructure solutions and workforce development commitments to support this expansion project. This includes a contribution of land for constructing a learning and training center within the LEAP industrial development, emphasizing the synergy between academia, industry, and government in fostering innovation.

Lilly's comprehensive investment strategy not only aims to meet immediate drug demand but also focuses on education enhancement and global workforce development, ensuring sustained innovation and accessibility to life-changing medicines.

Articles published about this story
More stories